BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 33798211)

  • 1. Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review.
    Byambasuren O; Dobler CC; Bell K; Rojas DP; Clark J; McLaws ML; Glasziou P
    PLoS One; 2021; 16(4):e0248946. PubMed ID: 33798211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic.
    Popova AY; Smirnov VS; Andreeva EE; Babura EA; Balakhonov SV; Bashketova NS; Bugorkova SA; Bulanov MV; Valeullina NN; Vetrov VV; Goryaev DV; Detkovskaya TN; Ezhlova EB; Zaitseva NN; Istorik OA; Kovalchuk IV; Kozlovskikh DN; Kombarova SY; Kurganova OP; Lomovtsev AE; Lukicheva LA; Lyalina LV; Melnikova AA; Mikailova OM; Noskov AK; Noskova LN; Oglezneva EE; Osmolovskaya TP; Patyashina MA; Penkovskaya NA; Samoilova LV; Stepanova TF; Trotsenko OE; Totolian AA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis.
    Bobrovitz N; Arora RK; Cao C; Boucher E; Liu M; Donnici C; Yanes-Lane M; Whelan M; Perlman-Arrow S; Chen J; Rahim H; Ilincic N; Segal M; Duarte N; Van Wyk J; Yan T; Atmaja A; Rocco S; Joseph A; Penny L; Clifton DA; Williamson T; Yansouni CP; Evans TG; Chevrier J; Papenburg J; Cheng MP
    PLoS One; 2021; 16(6):e0252617. PubMed ID: 34161316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Spijker R; Taylor-Phillips S; Adriano A; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Dittrich S; Emperador D; Hooft L; Leeflang MM; Van den Bruel A;
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013652. PubMed ID: 32584464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Fox T; Geppert J; Dinnes J; Scandrett K; Bigio J; Sulis G; Hettiarachchi D; Mathangasinghe Y; Weeratunga P; Wickramasinghe D; Bergman H; Buckley BS; Probyn K; Sguassero Y; Davenport C; Cunningham J; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Struyf T; Van den Bruel A; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Deeks JJ;
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013652. PubMed ID: 36394900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study.
    Álvarez-Antonio C; Meza-Sánchez G; Calampa C; Casanova W; Carey C; Alava F; Rodríguez-Ferrucci H; Quispe AM
    Lancet Glob Health; 2021 Jul; 9(7):e925-e931. PubMed ID: 34022148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys.
    Angulo FJ; Finelli L; Swerdlow DL
    JAMA Netw Open; 2021 Jan; 4(1):e2033706. PubMed ID: 33399860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
    Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
    Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
    COVID-19 Cumulative Infection Collaborators
    Lancet; 2022 Jun; 399(10344):2351-2380. PubMed ID: 35405084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.
    He Z; Ren L; Yang J; Guo L; Feng L; Ma C; Wang X; Leng Z; Tong X; Zhou W; Wang G; Zhang T; Guo Y; Wu C; Wang Q; Liu M; Wang C; Jia M; Hu X; Wang Y; Zhang X; Hu R; Zhong J; Yang J; Dai J; Chen L; Zhou X; Wang J; Yang W; Wang C
    Lancet; 2021 Mar; 397(10279):1075-1084. PubMed ID: 33743869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study.
    Stefanelli P; Bella A; Fedele G; Pancheri S; Leone P; Vacca P; Neri A; Carannante A; Fazio C; Benedetti E; Fiore S; Fabiani C; Simmaco M; Santino I; Zuccali MG; Bizzarri G; Magnoni R; Benetollo PP; Merler S; Brusaferro S; Rezza G; Ferro A
    Clin Microbiol Infect; 2021 Apr; 27(4):633.e1-633.e7. PubMed ID: 33253941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High SARS-CoV-2 Seroprevalence in Rural Peru, 2021: a Cross-Sectional Population-Based Study.
    Moreira-Soto A; Pachamora Diaz JM; González-Auza L; Merino Merino XJ; Schwalb A; Drosten C; Gotuzzo E; Talledo M; Arévalo Ramirez H; Peralta Delgado R; Bocanegra Vargas S; Drexler JF
    mSphere; 2021 Dec; 6(6):e0068521. PubMed ID: 34817236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study.
    Spinelli MA; Lynch KL; Yun C; Glidden DV; Peluso MJ; Henrich TJ; Gandhi M; Brown LB
    Lancet HIV; 2021 Jun; 8(6):e334-e341. PubMed ID: 33933189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.
    Hoballah A; El Haidari R; Siblany G; Abdel Sater F; Mansour S; Hassan H; Abou-Abbas L
    BMC Infect Dis; 2022 Jan; 22(1):42. PubMed ID: 35012464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.
    Stringhini S; Wisniak A; Piumatti G; Azman AS; Lauer SA; Baysson H; De Ridder D; Petrovic D; Schrempft S; Marcus K; Yerly S; Arm Vernez I; Keiser O; Hurst S; Posfay-Barbe KM; Trono D; Pittet D; Gétaz L; Chappuis F; Eckerle I; Vuilleumier N; Meyer B; Flahault A; Kaiser L; Guessous I
    Lancet; 2020 Aug; 396(10247):313-319. PubMed ID: 32534626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19).
    Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP;
    Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.
    Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP
    JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhão.
    Silva AAMD; Lima-Neto LG; Azevedo CMPES; Costa LMMD; Bragança MLBM; Barros Filho AKD; Wittlin BB; Souza BF; Oliveira BLCA; Carvalho CA; Thomaz EBAF; Simões-Neto EA; Leite Júnior JF; Cosme LMSS; Campos MAG; Queiroz RCS; Costa SS; Carvalho VA; Simões VMF; Alves MTSSBE; Santos AMD
    Rev Saude Publica; 2020; 54():131. PubMed ID: 33331525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.